the antigens that drive RA immune responses, and therefore, it is not known which PADs to target for this treatment approach to be most effective. PAD2 and PAD4 are expressed in immune cells and are overexpressed in RA synovium (7) . PAD2 is broadly expressed in sites including skin, intestine, brain, muscle, and hematopoietic cells, while PAD4 expression is restricted to certain cell types, including neurons and neutrophils. PAD4 is unique among PAD family members, because it harbors a nuclear localization sequence and is required for NETosis (8) (9) (10) (11) .
Our group recently showed that neutrophils undergoing cell death, induced by either NETosis or necrosis, release both PAD2 and PAD4, and this leads to citrullination of extracellular fibrinogen (12) . Surface plasmon resonance imaging of PAD2-and PAD4-citrullinated fibrinogen has demonstrated that the 2 isoforms citrullinate different arginine residues within fibrinogen (13) , with PAD2 causing more extensive arginine citrullination than PAD4. Because RA-related autoantibody responses to citrullinated fibrin are closely restricted (14) , we hypothesized that immunoreactivity to PAD2-and PAD4-citrullinated fibrinogen may differ. We therefore compared RA antibody levels to PAD2-and PAD4-citrullinated fibrinogen and observed that RA patient plasma harbors increased levels of antibodies to fibrinogen when it is citrullinated by PAD4. Mass spectrometry (MS)-based analysis of our samples revealed that although both enzymes heavily citrullinated arginines in a hot spot region between position 44 and position 74, PAD2 citrullinates more consistently, while PAD4 citrullinates intermittently, and this provides a more diverse collection of target citrullinated epitopes against which antibodies are produced.
PATIENTS AND METHODS
Patients and healthy subjects. Plasma samples were obtained from 12 patients with established anti-CCP antibodypositive RA who met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA (15) . Plasma samples were also collected from healthy subjects who were matched with patients for sex and age within 5 years. The ethics review board of Rockefeller University Hospital approved this study, and all study subjects gave written informed consent.
Enzyme-linked immunosorbent assay (ELISA). PAD2 (item no. 10785; Cayman Chemical) or PAD4 (item no. 10500; Cayman Chemical) was autocitrullinated by incubating 10 mg/ml in 100 mM Tris buffer (Sigma-Aldrich), 10 mM CaCl 2 , and 5 mM dithiothreitol (DTT) (Affymetrix) at 378C overnight. Effective citrullination was verified using Citrulline-specific Probe (item no. 16172; Cayman Chemical). Microtiter plates (Nunc) were coated for 1 hour at room temperature with fibrinogen, PAD4-citrullinated fibrinogen (item no. 400076; Cayman Chemical), PAD2-citrullinated fibrinogen (item no. 18473; Cayman Chemical), citrullinated PAD4, citrullinated PAD2, or peptide antigens (synthesized by 9-fluorenylmethoxycarbonyl chemistry), at 5 mg/ ml in 0.05M carbonate-bicarbonate buffer (pH 9.6). Plates were washed with 0.05% Tween 20 (Sigma-Aldrich) in phosphate buffered saline (PBS) (Cellgro), and blocked for 1 hour with 1% bovine serum albumin (BSA) in PBS. Plasma, diluted at various concentrations in 1% BSA/PBS, was added for 1 hour. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG (Jackson ImmunoResearch) was added for detection. Bound antibodies were revealed using the chromogenic substrate 3,3 0 ,5,5 0 -tetramethylbenzidine (Sigma-Aldrich), and the reaction was stopped with 2M H 2 SO 4 . Plates were read at optical density (OD) 450 nm.
Avidity was measured by adding various concentrations of sodium thiocyanate (Sigma-Aldrich) to ELISA plates. Avidity is presented as the avidity index, which was calculated by dividing the amount of residual antibodies bound to the antigen-coated plate by the amount of antibodies bound in the absence of a chaotropic agent.
Western blotting. Either PAD4-citrullinated fibrinogen or PAD2-citrullinated fibrinogen (1 mg per lane) was resolved by polyacrylamide gel electrophoresis (PAGE) and transferred to PVDF membranes (Millipore). The membranes were blocked in 5% nonfat milk in Tris buffered saline (TBS) containing 0.1% Tween 20 for 1 hour at room temperature. Membranes were probed with the following: monoclonal anti-citrullinated fibrinogen (1:1,000) (Cayman Chemical), monoclonal anti-PAD2 antibody (1:500) (catalog no. H00011240-M01; Abnova) (16), anti-PAD4 antibody (1:1,000) (ab128086; Abcam) (17) , monoclonal antifibrinogen (1:500) (ab10066; Abcam), or RA patient plasma diluted 1:1,000 in 5% nonfat milk in TBS containing 0.1% Tween 20. Bound immunoglobulin was detected with HRP-labeled secondary antibodies (Life Technologies) and visualized using an enhanced chemiluminescence system (Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate; PerkinElmer).
For preadsorption assays, RA patient plasma samples, diluted 1:1,000 in TBS containing 0.1% Tween 20 and 5% nonfat milk, were preincubated with PAD2-citrullinated fibrinogen protein or peptide (10 mg/ml) for 1 hour at 37 C prior to being used to probe membranes for 2 hours at room temperature. The density of the bands was evaluated using ImageJ 1.46r software (National Institutes of Health).
Plasmin cleavage assay. PAD4-citrullinated fibrinogen (0.2 mg/ml) was incubated with 0.006 mg/ml plasmin (SigmaAldrich) in 20 mM Tris HCl, 2 mM CaCl 2 , and 5 mM DTT for 1 hour at 37 C. One microgram of PAD4-citrullinated fibrinogen and 5 mg of plasmin-digested PAD4-citrullinated fibrinogen were resolved using 12% sodium dodecyl sulfate (SDS)-PAGE gels. Proteins were transferred to PVDF membranes and probed with RA patient plasma (1:1,000) as described above.
Liquid chromatography (LC)-MS. One microgram of each sample (unmodified, PAD2-modified, or PAD4-modified fibrinogen) was separated by SDS-PAGE and stained with Coomassie brilliant blue. Gel bands corresponding to masses demonstrating reactivity against patient antiplasma by Western blot analysis were excised for in-gel proteolytic digestion (18) . In short, following reduction of cysteines with DTT and alkylation with iodoacetamide (Sigma-Aldrich), digestion was conducted with either trypsin (Promega) and Lys-C (Waco Chemicals) or chymotrypsin (Promega). Samples were processed and analyzed in triplicate to provide additional confidence regarding assignment. Following overnight incubation, peptides were extracted from gel pieces with acetonitrile, dried, and resuspended in 2% acetonitrile/0.1% trifluoroacetic acid. Each sample was analyzed by nano-LC tandem MS (LC-MS/MS) (Dionex 3000 HPLC coupled to Q Exactive MS system; Thermo Scientific). Peptides were separated at 200 nl/minute using a gradient increasing from 5% to 45% acetonitrile/0.1% acid in 60 minutes. Peptides were loaded onto a Trap column prior to separation on a Packed Emitter C18 column (75 mm 3 12 cm; 3-mm particles) (Nikkyo Technos Co., Ltd).
For data-dependent analysis of peptide modification identification, the mass spectrometer was operated in "preferred mode": fragmentation of up to 20 ions per cycle using an underfill ratio of 1%. For quantitation and specific site assignment of arginine citrullination in the identified hot spot (R44, R47, R53, R60, R72, and R74), parallel reaction monitoring (PRM) (19) was used for quantification, using parent and fragment ions for distinct modification sites. MS spectra (mass/charge [m/z] 300-1,400) were recorded at a resolution of 70,000 (automatic gain control [AGC] 5e5) and MS/MS spectra at 17,500 (AGC 1e5) with a lowest m/z of 100. Generated LC-MS/MS data were queried against the UniProt complete human proteome (March 2016) using the Mascot search engine, with carbamidomethylation of cysteine as a static modification and the following variable modifications: oxidation of methionine, acetylation of N-terminal protein, deamidation of asparagine and glutamine, and citrullination of arginine.
Identifications were filtered to include only precursor masses of ,5 parts per million and highest peptide-spectrum matches ranking, and false discovery rates of ,1% were controlled using a Percolator algorithm (20) . Deamidation was included to allow consideration of de facto asparagine/glutamine deamidation and the isobaric citrullination modification. Up to 4 missed cleavages were allowed for the chymotrypsin searches, while up to 7 missed cleavages were allowed for the trypsin searches (because citrullination will lead to missed cleavage of modified arginines). For the trypsin-digested samples, peptides identified as citrullinated were required to contain a missed cleavage following a modified arginine. Skyline (an open-source document editor for creating and analyzing targeted proteomics experiments) (21) was used for quantitation of PRM data for the relative modification site comparison, by summing precursor peak areas. In the case of isobaric modification variants, the parent signal was distributed proportionally to the discriminating fragment ion areas. A spectral library generated from the Mascot searches was used to assign peak identity.
Statistical analysis. The unpaired t-test was used to compare ELISA-derived OD values between normal donor plasma and RA patient plasma. The paired t-test was used to compare ELISA-derived OD values for plasma from individual donors to PAD4-citrullinated fibrinogen and PAD2-citrullinated fibrinogen. Wilcoxon's matched pairs signed rank test was used to compare the normalized band intensities of Western blots. Oneway analysis of variance and Tukey's test for multiple comparisons were used to evaluate statistical differences between 3 different titers in the avidity ELISA at a concentration of 3N sodium thiocyanate. P values less than 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism software.
RESULTS
Higher levels of antibodies to PAD4-citrullinated fibrinogen than to PAD2-citrullinated fibrinogen in RA patient plasma, as measured by ELISA. We tested responses of normal donor and RA patient plasma to fibrinogen as well as PAD2-and PAD4-citrullinated fibrinogen. The characteristics of the RA patients are shown in the Supplementary Table (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40035/abstract). Notable features of this cohort are that 100% of patients harbored high-titer CCP antibodies, and 66% of patients had rheumatoid nodules. Otherwise, the patients had varying disease durations, disease activity levels, and exposures to medications. As expected, at low dilutions, neither normal donors nor RA patients had antibodies to unreacted (native) plasma-derived fibrinogen, while antibody binding to both PAD2-and PAD4-citrullinated fibrinogen was significantly increased in RA patients ( Figure 1A) .
To determine the relative reactivity of RA patient plasma to PAD4-citrullinated fibrinogen versus PAD2-citrullinated fibrinogen, we tested a range of plasma dilutions. At high dilutions (1:250 and 1:1,000), binding to PAD4-citrullinated fibrinogen was significantly greater than that to PAD2-citrullinated fibrinogen, although binding was similar at low dilutions (1:40 and 1:100), likely due to assay saturation at low dilutions ( Figure 1B ). The ratio of plasma binding to PAD4-or PAD2-citrullinated fibrinogen in each patient was calculated as the OD of PAD4-citrullinated fibrinogen/OD of PAD2-citrullinated fibrinogen. The mean ratios of PAD4-citrullinated:PAD2-citrullinated fibrinogen at the 1:250 and 1:1,000 dilutions were 1.26 (95% confidence interval [95% CI] 1.18 -1.35) and 1.39 (95% CI 1.24 -1.53), respectively ( Figure 1C ). To test whether the increased recognition of PAD4-citrullinated fibrinogen was attributable to antibodies against PAD4 itself, we also measured reactivity against PAD2 and PAD4. We did not detect reactivity to PAD4 or PAD2 that was greater than reactivity to buffer alone at either 1:250 or 1:1,000 ( Figure 1D ).
Better binding of RA antibodies to PAD4-citrullinated fibrinogen than to PAD2-citrullinated fibrinogen on Western blotting. One limitation of using ELISA to measure RA antibody responses to citrullinated fibrinogen is that the relative importance of the 3 polypeptide chains (a, b, and g) cannot be distinguished. To address this question, we resolved equal amounts of PAD4-citrullinated fibrinogen and PAD2-citrullinated fibrinogen in adjacent lanes on multiple Western blots and probed with monoclonal anti-citrullinated fibrinogen b-chain (fibrinogen b) antibody (see Supplementary Figure 1A Figure 1E) . At this dilution, the individual RA patient plasma samples most consistently recognized a band just above 52 kd, consistent with the known molecular weight of fibrinogen b (56 kd). Plasma from some patients also recognized a higher molecular weight band, just above 76 kd, which likely represents recognition of the a-chain of fibrinogen (fibrinogen a), given that there was no recognition of PAD2 or PAD4 itself on ELISA. The band intensity of the 56-kd region was quantitated using densitometric analysis. RA patient antibodies generated significantly more intense bands to PAD4-citrullinated fibrinogen compared to PAD2-citrullinated fibrinogen (Figure 2) .
There was no difference in RA antibody avidity to PAD4-or PAD2-citrullinated fibrinogen. RA patient antibodies could display increased binding to PAD4-citrullinated fibrinogen on ELISA and Western blotting due to differences in avidity (increased cumulative binding affinity to PAD4-citrullinated fibrinogen) or specificity (more relevant epitopes on PAD4-citrullinated fibrinogen). To compare the avidity of RA antibodies, we compared the ELISA-derived OD values of RA patient plasma incubated with either PAD4-or PAD2-citrullinated fibrinogen and various concentrations of a chaotropic agent, sodium thiocyanate.
Three patient plasma samples that produced 56-kd bands but not 76-kd bands on Western blot were chosen for this assay to specifically measure binding avidity to citrullinated fibrinogen b, since it is more commonly recognized than citrullinated fibrinogen a in our studies of very-hightiter antibodies. Significantly more chaotropic agent was required to inhibit binding at increasing antibody titers, indicating a significant increase in avidity with increased titers (Figure 3) . The avidity index and the antibody titer were correlated in both the PAD4-and PAD2-citrullinated fibrinogen samples. There was no difference, however, in the avidity of RA antibodies to PAD4-or PAD2-citrullinated fibrinogen at high titers (1:250 or 1:1,000), which produced a robust difference in both ELISA and Western blot results. Although it is possible that there was a subtle difference in avidity that was below the limit of detection in this assay, this potential difference is less significant than the difference conferred by increasing titers. There was a trend toward an increased avidity index for PAD2-citrullinated fibrinogen relative to PAD4-citrullinated fibrinogen at low titers (1:40), but this was not significant. For the 3 samples tested, differential avidity cannot explain the increased RA antibody binding of PAD4-citrullinated fibrinogen.
More intermittent citrullination at hot spot region of fibrinogen by PAD4, as measured by MS. It is possible that the difference in RA antibody recognition of PAD2-and PAD4-citrullinated fibrinogen is due to a difference in the level of citrullination in the samples. To quantify the extent of citrullination of either noncitrullinated, PAD2-citrullinated, or PAD4-citrullinated fibrinogen, we performed bottom-up MS of the 56-kd band (fibrinogen b) to identify and quantify modified versus unmodified peptides. Fibrinogen b was chosen for this quantitative analysis, because RA patient plasma diluted 1:1,000 bound fibrinogen b more frequently than fibrinogen a. Distal to the signal peptide, starting at position 31, protein sequence coverage was nearly complete (98%). This coverage accounted for all arginines. We identified a "hot spot" of arginine citrullination at positions R44, R47, R53, R60, R72, and R74 
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BLACH ERE ET AL in both PAD2-and PAD4-modified fibrinogen b ( Figure  4A ). At these sites, citrullination was strikingly more abundant than that at other downstream citrullination sites. The citrullination hot spot region between positions R44 and R74 was analyzed in depth to identify differences in citrullination between PAD2-and PAD4-modified samples. Both PAD2 and PAD4 citrullinated R44 and R47 fully (.99%) ( Figure 4B ). Interestingly, residues at these positions were also citrullinated, but at a lower level (8%), in unreacted (native) fibrinogen samples. Although PAD2 treatment resulted in 95% citrullination of all 4 remaining hot spot residues (R53, R60, R72, and R74), PAD4 treatment resulted in complete citrullination of all 4 residues in only 42% of peptides identified ( Figure 4C ). In the majority of peptides, R53, R60, R72, and R74 were citrullinated intermittently. The next most commonly identified combination of PAD4-citrullinated arginines was at positions R53/R60, followed by R53 only, and R53/R60/R72.
In addition to this hot spot region between positions R44 and R74, citrullination was detected at low levels at several sites in the C-terminal region of the fibrinogen b protein. Although the initial analysis detected putative sites of low-level citrullination throughout the fibrinogen b protein, this low level of citrullination can be difficult to discriminate from artifactual deamidation of asparagine and glutamine, because these modifications are isobaric. These sites were manually validated to confirm that fragmentation spectra coverage could differentiate from any adjacent Figure 4 . Fibrinogen b-chain (fibrinogen b) arginine sites 44-74 are a hot spot of citrullination that are uniformly modified by peptidylarginine deiminase type 2 (PAD2) and intermittently modified by PAD4. Unmodified, PAD2-citrullinated, or PAD4-citrullinated fibrinogen was enzymatically digested and analyzed by mass spectrometry. A, Summed signal (PAD2 and PAD4) of peptides containing a citrullinated arginine, plotted as a function of the amino acid residue number for fibrinogen b. The green bars depict the residues covered based on peptides with a false discovery rate of ,1%. B and C, Relative abundance of identified peptide signals carrying modifications at R44 and R47 (B) and R53, R60, R72, and R74 (C) in PAD2-citrullinated, PAD4-citrullinated, and unreacted (control) fibrinogen. asparagine or glutamine residues. A list of validated citrullination sites and their relative quantitation by PRM are shown in Table 1 . Taken together, these data indicate that although both PAD2 and PAD4 hypercitrullinate a hot spot region between R44 and R74 on fibrinogen b, PAD4-mediated citrullination is more intermittent at residues R53, R60, R72, and R74.
Better binding of RA antibodies to PAD4-citrullinated fibrinogen hot spot region due to a broader array of epitopes. To determine whether the preferential binding of PAD4-citrullinated fibrinogen was due to recognition of partially citrullinated peptides in the hot spot region (spanning positions 44 to 74) or peptides citrullinated by PAD4 only (positions 334 and 478), we performed an ELISA to compare RA and normal antibody responses to citrullinated peptides. Citrullinated filaggrin peptide 1 (cfc-1) was used as a positive control in this experiment, and cfc-0 (the noncitrullinated isoform) was used as a negative control. Antibodies in half of the RA patient samples tested recognized the positive control peptide cfc-1, while none of these antibodies recognized the negative control peptide cfc-0 ( Figure 5A ).
We did not identify a single citrullinated fibrinogen b peptide that was consistently more immunogenic when it was only partially citrullinated. Instead, there was a diverse array of peptide recognition. This variability in RA antibody responses to various citrullinated isoforms of the same peptide region is reminiscent of the original article mapping epitopes of citrullinated filaggrin (22) . The clinically useful tests for antibodies to citrullinated filaggrin peptides include an array of peptides derived from filaggrin spanning positions 306 to 324. This region includes 5 arginine residues, and while only 36% of RA antibodies bind the peptide when the first arginine residue is citrullinated, the sensitivity of the assay is improved considerably to 76% when it includes a mix of 9 peptides spanning this same region but with different citrullination sites (23) . Because PAD4 variably citrullinates arginines in the hot spot region, it stands to reason that the improved RA antibody recognition of PAD4-citrullinated fibrinogen indicates that RA antibodies bind an assortment of citrullinated epitopes, and that citrullination by PAD4 results in a broader array of potential target epitopes.
To confirm that the increased binding of plasma RA antibodies to PAD4-citrullinated fibrinogen was due to the availability of epitopes that are not present in PAD2-citrullinated fibrinogen, we preadsorbed RA patient plasma with PAD2-citrullinated fibrinogen at various concentrations and tested whether there was a remaining antibody capable of binding PAD4-citrullinated fibrinogen. Preadsorption with increasing concentrations of PAD2-citrullinated fibrinogen led to a sharp decrease in recognition of PAD2-citrullinated fibrinogen but relatively preserved binding of PAD4-citrullinated fibrinogen ( Figure  5B ). Although RA patient antibodies bound both PAD2-and PAD4-citrullinated fibrinogen, this result establishes that PAD4-citrullinated fibrinogen includes additional epitopes that can be recognized by RA patient plasma.
To compare the relative importance of the Nterminal hot spot region and the C-terminal citrullination sites (R334 and R478), we treated PAD4-citrullinated fibrinogen with plasmin, which cleaves fibrinogen b at positions 152 and 163. This results in the generation of 2 main fibrinogen b fragments (23) . The C-terminal, 38-kd fragment D spans residues 164-491 and therefore includes the PAD4-specific, low-abundance citrullination sites R334 and R478. The smaller N-terminal (8 kd), fragment E spans positions 30-153, which includes the hot spot region of citrullination. Citrullinated fibrinogen was incubated with plasmin under conditions sufficient to cause partial digestion of the protein and was resolved by SDS-PAGE. A positive control polyclonal anti-fibrinogen b antibody detected intact fibrinogen b (56 kd) and the bchain fragment D (38 kd) but did not detect the b-chain fragment E ( Figure 5C ), even when increasing the amount 5-fold and detecting this fragment at its expected molecular weight of 8 kd by Coomassie brilliant blue staining (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40035/abstract).
Loading an increased amount of cleaved fibrinogen revealed the presence of heavy-chain antibodies at 52 kd (fibrinogen was purified from human plasma). All RA antibodies tested in this manner bound intact fibrinogen more than fragment D. The relative band intensity of RA antibody recognition of fragment D relative to intact fibrinogen ranged from 1% to 13% ( Figure 5C ). The consistently weaker recognition of fragment D, relative to intact fibrinogen, indicated that RA antibodies likely bind to the N-terminal region, which spans residues 31 to 153. It should be noted that plasmin cleavage could have directly disrupted an important site of antibody recognition; however, there is only 1 arginine residue in proximity to a plasmin cleavage site (R158), and careful re-analysis of MS data failed to detect modification of this arginine in our PAD-modified fibrinogen samples.
To test whether citrullinated peptides from the hot spot region encompass the critical antibody recognition sites, we compared the effect of preadsorbing RA patient plasma with either native or citrullinated isoforms of peptides spanning sites 41-77. Preadsorption of 3 RA patient plasma samples with citrullinated hot spot peptide pools decreased recognition of fibrinogen b by 77%, 53%, and 80%, while preadsorption with native peptide pools decreased recognition by 0% to 20% ( Figure 5D ). We therefore conclude that the key site of RA antibody recognition of citrullinated fibrinogen resides in the hot spot region spanning R44 to R74. Taken together, these data demonstrate that RA antibodies bind PAD4-citrullinated fibrinogen more than PAD2-citrullinated fibrinogen, because intermittent citrullination of the hot spot region offers a more diverse assortment of citrullinated epitopes.
DISCUSSION
High-titer CCP ("high-positive ACPA") contributes 3 points to the 2010 ACR/EULAR classification criteria score for RA (15) . According to these criteria, "highpositive" refers to values that are .3 times the upper limit of normal (ULN). Because few commercially available assays extend titers beyond 10 times the ULN, relatively little is known about very-high-titer CCP antibodies. The likelihood of undifferentiated arthritis progressing to persistent arthritis further increases in patients with veryhigh-titer antibodies (.10 times the ULN) relative to those with high-titer antibodies (4-10 times the ULN) (24) , suggesting that there may also be a clinically important distinction between high-titer and very-high-titer CCP antibodies. Considering that very-high-titer antibodies are also very-high-avidity antibodies, it is conceivable that they play a more important role in immune targeting and merit further exploration. In this study, we demonstrated that at very high titers, RA antibodies demonstrate preferential binding of PAD4-citrullinated fibrinogen compared to PAD2-citrullinated fibrinogen. Bearing in mind the broad repertoire of citrullinated antigens targeted by RA antibodies, one might have predicted that decreased antibody binding would be attributable to less efficient citrullination in the PAD2-citrullinated fibrinogen samples, but MS analysis of our samples demonstrated less efficient citrullination in PAD4-citrullinated fibrinogen.
An important limitation of this study is that it demonstrates antibody binding to citrullinated fibrinogen generated in vitro, and there may be differences in the activity of PAD2 and PAD4 in vivo. The citrullinated fibrinogen used in this study was generated by adding either PAD2 or PAD4 in buffer containing 10 mM CaCl 2 and incubated overnight at 378C (according to the instructions of the manufacturer), which likely represents a higher calcium concentration and longer duration of exposure than occurs in vivo. Interestingly, despite the use of conditions that were optimized to maximize citrullination rather than model conditions in vivo, the validated citrullination sites detected were restricted to 2 domains in the fibrinogen b protein: the N-terminal central domain and the Cterminal globular domain. We could not confirm citrullination at arginine sites in the coiled-coil region.
Although the reaction conditions for citrullinating fibrinogen used in these assays make it difficult to conclude that PAD4 plays a more important role in generating autoantigen targets of RA antibodies, it does not detract from the observation that RA antibodies distinguish fibrinogen b with subtle differences in citrullination profiles. In support of the in vivo relevance of the citrullination hot spot identified here, citrullinated fibrinogen b epitopes derived from the hot spot region have been identified in RA synovial tissue (25) and synovial fluid (26) as well as circulating RA immune complexes (27) .
In summary, the current study demonstrates that very-high-titer antibodies bind PAD4-citrullinated fibrinogen more than PAD2-citrullinated fibrinogen, and that this could not be attributed to increased citrullination in PAD4-reacted samples. Instead, while both PAD2 and PAD4 heavily citrullinate a hot spot region between R44 and R74, the PAD4 citrullination profile is more intermittent. Other studies of ACPAs have largely used PAD2-modified target proteins or peptides with citrullination of all possible arginines. Our study indicates that high-titer RA antibodies preferentially bind PAD4-citrullinated fibrinogen, because it produces an assortment of citrullinated isoforms from a hot spot of fibrinogen b citrullination. In the future, it would be useful to compare the relative binding of high-titer RA antibodies to other known citrullinated target antigens modified by PAD2 or PAD4, to evaluate the generalizability of this result.
